CUPERTINO, Calif., Jan. 6 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 22nd
Annual Healthcare Conference. The conference is taking place January 12-15th
at The Westin St. Francis Hotel in San Francisco. Dr. James E. Brown,
President and Chief Executive Officer will be presenting at the conference on
Thursday, January 15th at 11:00 a.m. Pacific Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
There will be a live webcast of the presentation from the Conference. The
webcast will be available on DURECT’s website at www.www.durect.com under the
Calendar of Events section of “Investor Relations.” The presentation will also
be available for replay on DURECT’s website for a period of 30 days after the
conference.
About DURECT Corporation
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical
products. DURECT’s goal is to deliver the right drug to the right site in the
right amount at the right time. In addition to its rights to the CHRONOGESIC
product, DURECT owns three proprietary drug delivery platform technologies,
including the SABER(TM) Delivery System (a patented and versatile depot
injectable useful for protein delivery), the MICRODUR(TM) Biodegradable
Microparticulates (microspheres injectable system) and the DURIN(TM)
Biodegradable Implant (drug-loaded implant system).
NOTE: CHRONOGESIC(R), SABER(TM), MICRODUR(TM) and DURIN(TM) are trademarks
of DURECT Corporation.
The statements in this press release regarding DURECT’s products in
development, product development plans and projected financial results are
forward-looking statements involving risks and uncertainties that can cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not limited to,
DURECT’s ability to complete the design, development, and manufacturing
process development of its products, manufacture and commercialize its
products, obtain product and manufacturing approvals from regulatory agencies,
manage its growth and expenses, manage relationships with third parties,
finance its activities and operations, as well as marketplace acceptance of
DURECT’s products. Further information regarding these and other risks is
included in DURECT’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 filed with the SEC on March 14, 2003 and other periodic
reports filed with the SEC under the heading “Factors that may affect future
results.”
CHRONOGESIC is under development by DURECT and has not been submitted or
approved for commercialization by the US Food and Drug Administration or other
health authorities.
SOURCE DURECT Corporation
CONTACT:
Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation
408-777-1417
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840
/Web site: http://www.www.durect.com